Introduction
============

Cervical cancer is a leading cause of cancer death in women in developing countries;[@b1-ott-9-1361] in People's Republic of China, it represents a great disease burden, with a high incidence of 7.5/100,000 and mortality of 3.4/100,000.[@b2-ott-9-1361] For patients with Federation International of Gynecology and Obstetrics stage IB1--IIA2 cervical cancer, treatment of choice consists of radical hysterectomy (RH) with pelvic lymphadenectomy or concurrent chemoradiotherapy.[@b1-ott-9-1361],[@b3-ott-9-1361] Compared with concurrent chemoradiotherapy, RH can provide more accurate staging information, remove the primary tumor, thereby obviating the need for brachytherapy and reducing the risk of fibrosis of the vagina, preserve ovarian function in selected cases, dissect the bulky (2--3 cm) positive nodes that are less likely to be sterilized with primary radiation, and detect the lymph node involvement which guides decisions about subsequent radiotherapy.[@b4-ott-9-1361]--[@b7-ott-9-1361] For these advantages, RH is an important and viable alternative for operable patients.

Gynecologic oncology is a unique subspecialty involved in the care of women with gynecologic cancers, which combines expertise in women's health, medicine, surgery, and oncology. Compared with gynecologists in other subspecialties, such as urogynecologists, general gynecologists, and subspecialists in reproductive endocrinology and infertility, gynecologic oncologists (GOs) often spend a large proportion of time in learning specific surgical skills that are necessary to manage gynecologic malignancies, so they may offer a much more meticulous surgery, which would translate into an improved survival. However, this potential association is based on conjecture, rather than evidence. We therefore conducted a retrospective cohort study and investigated the hypothesis that for cervical cancer patients who are treated with RH, the subspecialty of the referring gynecologist would affect their surgical and survival outcomes.

Materials and methods
=====================

Patients
--------

After obtaining approval from the Ethics Review Board of Sun Yat-sen Memorial Hospital, we reviewed the medical records of patients who received class III RH in Sun Yat-sen Memorial Hospital between January 2005 and June 2010. Inclusion criteria were: histologically confirmed invasive cervical cancer, age ≥16 years, and signed informed consent provided. Exclusion criteria were: patients with other metachronous or synchronous neoplasia, recurrent disease, metastatic disease, a history of previous radiation therapy, or a history of other types of malignancies or cervical melanoma.

Prior to surgery, all patients received a thorough evaluation which consisted of a complete physical and gynecologic examination, chest radiography, pelvic ultrasonography, and laboratory tests. Cystoscopy, sigmoidoscopy, and magnetic resonance imaging were performed only on clinical indication. Gynecologic examination was carried out by at least two senior gynecologists. The tumors were classified according to the Federation International of Gynecology and Obstetrics staging system.[@b3-ott-9-1361] All slides were examined by at least two authorized pathologists from our institution. Adjuvant radiotherapy was given to patients with positive parametrium, positive lymph nodes, or involved surgical margins, and patients with at least two of the following risk factors: greater than a third stromal invasion, lymphatic vascular space involvement, or tumor diameters ≥4 cm.[@b8-ott-9-1361] Postsurgical adjuvant chemotherapy was given at the discretion of the treating gynecologist.

After treatment, patients were followed up every 3 months for 2 years, every 6 months for the next 3 years, and once per year thereafter. Follow-up visits included physical examination and a Papanicolau smear of the vaginal vault.

A patient was considered as having seen a GO if her treating gynecologist was a member of the Gynecologic Oncology Society of the Chinese Medical Association. If an RH was performed as described in Rock's book, *TeLinde's Operative Gynecology*, it was defined as having adhered to surgical guidelines.[@b9-ott-9-1361] Follow-up information was obtained from office visits or telephone interviews. All events in our cohort were identified until death, loss to follow-up, or last follow-up. Cervical cancer-specific survival (CSS) was measured in months from the date of primary surgery until the date of death from cervical cancer or date of last follow-up. Recurrence-free survival (RFS) was defined as the length of time (in months) from the primary surgery to initial diagnosis of recurrence or date of last follow-up. Recurrence was confirmed by biopsy or imaging examinations. In the current study, more than half of the enrolled patients had locally advanced cervical cancer (LACC) (tumors of ≥4 cm in diameter). Because the optimal management of this patient subgroup is controversial, these patients were analyzed separately. Overall, the present study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology statement.[@b10-ott-9-1361] The study complied with the Declaration of Helsinki and was approved by the ethics review board of Sun Yat-sen Memorial Hospital (Permit Number: 201509132).

Statistical analyses
--------------------

Continuous variables were tested for normality by use of the Kolmogorov--Smirnov test. Normally distributed continuous variables were compared with the use of the standard Student's *t*-test, whereas continuous data with nonnormal distribution were compared by means of the Mann--Whitney *U*-test. Frequency distributions between categorical variables were analyzed with the use of the Chi-square test (*χ*^2^) or Fisher's exact test as appropriate. Kaplan--Meier survival curves were developed, and a log-rank test was used for the comparison of RFS and CSS. Cox proportional hazard models were used to identify the predictors for RFS and CSS. Variables that were statistically significant in the univariate Cox regression analysis were included in a multivariate analysis. A forward stepwise progression procedure was used with a significance level of 0.10 for removing variables. All tests were two-sided and a *P*-value \<0.05 was considered to be statistically significant. SPSS software (version 13.0, SPSS Inc., Chicago, IL, USA) was used for all analyses.

Results
=======

Clinical characteristics of the study population
------------------------------------------------

Of the 839 patients that were included in the present study, 553 (65.91%) were treated by GOs (GO group), while 286 (34.09%) were treated by other subspecialties (non-GO group). Demographic and clinicopathologic characteristics of the patients are summarized in [Table 1](#t1-ott-9-1361){ref-type="table"}. There were some differences between the two groups. Specifically, patients in the GO group were older (median, 53 vs 51 years, *P*=0.045), more likely to have comorbidities (50.8% vs 27.6%, *P*\<0.0001), had a lower incidence of positive surgical margin (2.2% vs 7.3%, *P*\<0.0001), and less likely to be treated with neoadjuvant chemotherapy (NACT) (14.1% vs 31.1%, *P*\<0.0001).

Operative characteristics and complications
-------------------------------------------

[Table 2](#t2-ott-9-1361){ref-type="table"} displays the operative characteristics and complications. Compared with the non-GO group, greater compliance with surgical guidelines was found in the GO group (*P*=0.003). Furthermore, more patients in the GO group received para-aortic lymph node sampling and dissection (9.8% vs 5.6%, *P*=0.038). Among patients in the GO group, we noted a shorter operative time (median, 180 vs 270 minutes, *P*\<0.0001), less estimated blood loss (median, 350 vs 425 mL, *P*\<0.0001), lower transfusion rate (26.9% vs 33.6%, *P*=0.046), more removed nodes (median, 25 vs 24, *P*=0.033), longer length of hospital stay (median, 16 vs 16 days, *P*=0.005), and longer duration until postvoid residual urine volume \>100 mL per day (16 vs 10 days, *P*\<0.0001). In terms of the intraoperative complications, patients in the non-GO group experienced more ureteric injury (1.4% vs 3.8%, *P*=0.027) and cystotomy (0.5% vs 2.4%, *P*=0.038). Regarding the risk of postoperative complications, more patients in the GO group experienced lymphocyst infection (4.0% vs 1.4%, *P*=0.041), whereas the incidence of fistula formation was lower in the GO group (0.4% vs 3.1%, *P*=0.002).

Survival
--------

### Survival outcomes

With a median follow-up of 36 months, 116 patients in the GO group (21.0%) and 86 patients in the non-GO group (30.1%) experienced recurrence, and the median overall recurrence was not reached in either group. The cumulative 5-year RFS rates were 79.0% and 69.9% in the GO and non-GO groups, respectively. A comparison of Kaplan--Meier curves for RFS showed a significant difference between the two groups (*P*=0.001; hazard ratio \[HR\] =0.64; 95% confidence interval \[CI\] \[0.48, 0.84\]) ([Figure 1A](#f1-ott-9-1361){ref-type="fig"}). There were 95 (17.2%) cervical cancer-related deaths in the GO group, compared to 73 (25.5%) in the non-GO group. The cumulative 5-year CSS of patients in the GO group was 82.8% compared with 74.5% for those in the non-GO group. A comparison of Kaplan--Meier curves for CSS demonstrated that the difference between the two groups was statistically significant (*P*=0.005; HR=0.64; 95% CI \[0.47, 0.87\]) ([Figure 1B](#f1-ott-9-1361){ref-type="fig"}).

### Univariate and multivariate analysis for survival

[Table 3](#t3-ott-9-1361){ref-type="table"} summarizes the univariate and multivariate analyses results for RFS. Univariate analysis showed care from a GO was found to be associated with RFS ([Table 3](#t3-ott-9-1361){ref-type="table"}). On multivariate analysis, care from a GO was identified as an independent factor of an improved RFS. [Table 4](#t4-ott-9-1361){ref-type="table"} summarizes the univariate and multivariate analysis results for CSS. After adjustment for other prognostic factors, multivariate analysis demonstrated that the treatment provided by a GO was an independent predictor of an improved CSS.

### Subgroup analysis for patients with LACC

Of the 839 patients, 428 (51.0%) had LACC (286 in the GO group and 142 in the non-GO group). The cumulative 5-year RFS and CSS for LACC patients in the GO group was 66.4% and 69.9% compared with 51.4% and 57.0% for LACC patients in the GG group. The Kaplan--Meier curves and log-rank tests are displayed in [Figure 1C and D](#f1-ott-9-1361){ref-type="fig"}, with significant differences in RFS (*P*=0.001; HR=0.55; 95% CI \[0.39, 0.77\]) and CSS (*P*=0.002; HR=0.57, 95% CI \[0.40, 0.82\]). Univariate and multivariate Cox proportional hazard analysis showed that care by GOs was associated with a significant improvement in RFS and CSS ([Table 5](#t5-ott-9-1361){ref-type="table"}).

Of the 428 patients with LACC, NACT was given to 162 (37.9%). The cumulative 5-year RFS and CSS for patients who underwent NACT was 56.2% and 60.5% compared with 64.7% and 68.8% for patients who did not receive NACT. No significant differences were found in RFS (*P*=0.105; HR=1.29; 95% CI \[0.95, 1.76\]) or CSS (*P*=0.096; HR=1.32; 95% CI \[0.95, 1.83\]) between the two groups categorized by NACT.

In univariate analysis, the use of NACT was not a significant predictive factor of RFS or CSS for patients with LACC. To explore the factors that were associated with the use of NACT, we conducted a multivariable stepwise linear-regression analysis. After adjusting for other confounders that included patient age, body mass index, tumor histology (nonsquamous vs squamous), and tumor Federation International of Gynecology and Obstetrics stage (IIA2 vs IB2), we found patients who did not undergo surgery by a GO (*P*\<0.0001; OR=0.25; 95% CI \[0.16, 0.39\]) and those with poorly differentiated tumors (G3) (*P*=0.013; OR=0.45; 95% CI \[0.24, 0.84\]) were more likely to receive NACT.

Discussion
==========

There is growing evidence that physicians with different subspecialty backgrounds affect treatment outcomes of patients with malignant disease.[@b11-ott-9-1361]--[@b13-ott-9-1361] However, for cervical cancer patients, this possible association has received little attention. We explored this hypothesis in the current study and did find significant differences in surgical and survival outcomes between patients who underwent RH by a GO and those who underwent RH by a non-GO. Our data suggest GOs confer significant benefit in terms of a shorter operative time, less estimated blood loss, lower transfusion rate, more removed nodes, and lower risks of cystotomy, ureteric injury, and postsurgical fistula formation. Furthermore, surgery performed by a GO has positive influence on survival rates, which could reduce the risk of disease recurrence and death from cancer by more than 35%, and this survival benefit even remains significant among patients with LACC.

More than 80% of our cohort did not receive regular cervical cancer screening. An important reason for the result is that an up to date, well-organized, nationwide cervical cancer screening system has not been established in People's Republic of China.[@b14-ott-9-1361],[@b15-ott-9-1361] In fact, among women who live in remote areas with limited access to health services, the basic awareness of the benefit of screening for cervical cancer is lacking.[@b14-ott-9-1361] Because tumors cannot be detected at an early stage or in a precancerous lesion, a proportion of patients have advanced disease at the time of diagnosis. This could also provide an explanation for our finding that more than 50% of the study population were diagnosed with LACC. Additionally, we found patients treated by GOs tended to be older, have a higher incidence of comorbidity, and have larger tumors. Considering the fact that there is no comprehensive referral system for women with gynecologic cancers in People's Republic of China and whether a patient is treated by a GO or a non-GO largely depends on patients' choice, we believe patients with multiple comorbidities and those with larger tumor would tend to select GOs and receive specialized diagnostic workup, treatment, and care.

Our multivariate analysis showed that care from a GO was an independent predictor of improved RFS and CSS; even in the subgroup of patients with LACC, its positive influence remains significant. Differences in the radicality and extent of lymphadenectomy might explain some differences in patient outcomes by the subspecialty of a gynecologist. Published evidence has shown that a larger number of lymph nodes removed are related to a better survival for patients with cervical cancer.[@b16-ott-9-1361],[@b17-ott-9-1361] In the present study, more lymph node yield was noted in the GO group, which suggests that GOs can allow a more thorough lymphadenectomy ([Table 2](#t2-ott-9-1361){ref-type="table"}). As lymph node micrometastases are independently associated with poor survival,[@b18-ott-9-1361] and those with greater numbers of lymph nodes analyzed are more likely to have lymph node micrometastases detected,[@b19-ott-9-1361] patients who receive care from GOs would benefit more from pelvic lymphadenectomy. In addition, compared with patients in the non-GO group, more patients in the GO group received para-aortic lymph node sampling and dissection. Therefore, patients with occult para-aortic nodal metastasis are more possible to be identified by GOs, and thus have a much better chance to receive timely extended-field radiation and an improved survival.[@b20-ott-9-1361],[@b21-ott-9-1361] We believe the differences in the number of removed lymph nodes may be related to the surgical dexterity. GOs usually own more proficient surgical skills compared with non-GOs and thus they have the capacity to deliver a much more radical lymphadenectomy. For the same reason, when para-aortic nodal enlargement is suspicious, they are more likely to perform para-aortic lymphadenectomy, which is associated with an increased risk of unmanageable bleeding of retroperitoneal blood vessels.

Variation in patient outcomes by subspecialty would also be related to the radicality of RH. Patients in the GO group were observed to experience a much longer duration until postvoid residual urine volume \<100 mL per day ([Table 2](#t2-ott-9-1361){ref-type="table"}). Bladder dysfunction after RH results from the injury to the pelvic autonomic nerves that supply to the muscle of the bladder,[@b22-ott-9-1361] and the more radical the surgery, the more severe the postoperative bladder dysfunction.[@b23-ott-9-1361] Considering this fact and our finding that GOs have greater compliance with surgical guidelines than other subspecialists, including urogynecologists, general gynecologists, and subspecialists in reproductive endocrinology and infertility ([Table 2](#t2-ott-9-1361){ref-type="table"}), we believe GOs have greater capacities to offer adequate surgical extent. In addition, consistent with published evidence, our analysis identified positive surgical margin as an independent factor of poor survival ([Tables 3](#t3-ott-9-1361){ref-type="table"} and [4](#t4-ott-9-1361){ref-type="table"}).[@b1-ott-9-1361] Because positive surgical margins were more frequently detected in patients of the non-GO group, from an oncological perspective, GOs will be more likely to ensure the radicality of RH and therefore better disease control.

NACT combined with RH has been used for several years in People's Republic of China.[@b7-ott-9-1361] In our study, NACT was prescribed to \~38% of patients with LACC ([Table 1](#t1-ott-9-1361){ref-type="table"}). NACT helps decrease tumor volume thereby making patients with clinically inoperable disease surgically amenable, increase the possibility of obtaining a wider negative surgical margin, and decrease the risk of lymph node metastasis.[@b24-ott-9-1361]--[@b27-ott-9-1361] Because of these advantages, in many parts of the world, such as Asia, Italy, and South America, NACT is used in up to 25% of patients.[@b28-ott-9-1361] Nevertheless, these benefits should be weighed against the potential risks. First, NACT can result in a longer duration of treatment, accelerate the repopulation of resistant cancer cells, and induce tumor cells to produce cross-resistance with radiotherapy.[@b29-ott-9-1361]--[@b31-ott-9-1361] Second, for patients with persistent lymph nodes metastasis, NACT has proven to be detrimental to survival.[@b32-ott-9-1361] Third, after NACT and RH, if radiotherapy is delivered, substantial morbidity will result from a combination of these three treatment modalities.[@b27-ott-9-1361] Finally, it should be noted that data in support of NACT are from only a small number of trials, and most of these trials are retrospective.[@b27-ott-9-1361] Since there is no definitive evidence that the use of NACT can translate into improvements in survival, we concur with the National Comprehensive Cancer Network guideline and consider NACT as not a necessary treatment for patients with LACC.[@b1-ott-9-1361] In the current study, more patients in the non-GO group received NACT; moreover, our multivariate analysis identified physicians who were not specialized in GO were independently associated with the utility of this treatment strategy. Considering the potential detrimental effects associated with NACT, we argue that GOs are more able to treat patients without unnecessary treatment or undue morbidity. A possible reason for the discrepancy between GOs' attitude and non-GOs' attitude to the utility of NACT could be that non-GOs may consider the tumor-size reduction after NACT helps the surgery achieve much wider resection margins. On the other hand, GOs follow current guidelines more strictly and tend to treat patients without unnecessary treatment or undue morbidity. Moreover, their surgical skills ensure an adequate tumor-free surgical margin without other adjuvant treatment, including NACT.

Our study had some limitations. First, it is a retrospective study; because of a lack of randomization and blinding, there is unbalanced and unrecognized bias. Second, the objectivity of the current study is dependent on accurate charting and documentation, which at times could be incomplete or inaccurate. Third, our data only reflect a single-institution experience. As the study population was from a specific geographical area, further investigation at multiple centers is needed. Fourth, some patients received adjuvant chemotherapy after surgery and radiotherapy. It was given at the discretion of the treating physician, and different chemotherapeutic regimens were used, so its exact impact on patient outcomes could not be clarified. Fifth, patient follow-up was performed by several physicians in our hospital, and hence the observational bias of recurrence events. Finally, not all patients received radiotherapy in the same institution, so the effect of variation in irradiation technique cannot be eliminated. The strengths of our study include the large sample size, relatively long duration of follow-up, and performance of the pathologic review by a single team of pathologists in our institution, which is particularly important if data on pathologic variables are analyzed. Moreover, to the best of our knowledge, this is the first study explicitly exploring the effects of physician subspecialty on outcomes of cervical cancer patients.

In conclusion, the present study identified the importance of the subspecialty of a gynecologist for cervical cancer patients. Because an RH that is performed by GOs affords an improvement in surgical and survival outcomes, and even among patients with LACC, this positive influence is still significant, we believe cervical cancer patients deserve to be referred to a center with GOs. Because of the limitations, we think further studies are warranted to confirm our conclusion.
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![Survival of patients with cervical cancer treated with radical hysterectomy.\
**Notes:** (**A**) Kaplan--Meier estimates of recurrence-free survival. The two groups are cervical cancer patients operated on by gynecologic oncologists and cervical cancer patients operated on by others. (**B**) Kaplan--Meier estimates of cancer-specific survival. The two groups are cervical cancer patients operated on by gynecologic oncologists and cervical cancer patients operated on by others. (**C**) Kaplan--Meier estimates of recurrence-free survival. The two groups are cervical cancer patients with locally advanced disease who are operated on by gynecologic oncologists and cervical cancer patients who are operated on by others. (**D**) Kaplan--Meier estimates of cancer-specific survival. The two groups are cervical cancer patients with locally advanced disease who are operated on by gynecologic oncologists and cervical cancer patients who are operated on by others.](ott-9-1361Fig1){#f1-ott-9-1361}

###### 

Baseline characteristics of the study population

                                                              GO group (n=553)    Non-GO group (n=286)   *P*-value
  ----------------------------------------------------------- ------------------- ---------------------- -----------
  Age (years), median (range)                                 53 (23--82)         51 (26--70)            0.045
  BMI (kg/m^2^), median (range)                               23.2 (17.5--31.0)   23.1 (17.8--30.2)      0.436
  Smoking, n (%)                                                                                         
   Never                                                      525 (94.9)          261 (91.3)             0.093
   Former                                                     13 (2.4)            9 (3.1)                
   Current                                                    3 (0.5)             1 (0.3)                
   Missing data                                               12 (2.2)            15 (5.2)               
  Regular screening, n (%)                                                                               
   No                                                         477 (86.3)          230 (80.4)             0.080
   Yes                                                        45 (8.1)            31 (10.8)              
   Missing data                                               31 (5.6)            25 (8.7)               
  Stage, n (%)                                                                                           
   IB1                                                        139 (25.1)          76 (26.6)              0.897
   IB2                                                        145 (26.2)          72 (25.2)              
   IIA1                                                       128 (23.1)          70 (24.5)              
   IIA2                                                       141 (25.5)          68 (23.8)              
  Tumor histology, n (%)                                                                                 
   Squamous cell                                              464 (83.9)          244 (85.3)             0.822
   Adenocarcinoma[a](#tfn1-ott-9-1361){ref-type="table-fn"}   61 (11.0)           30 (10.5)              
   Other[b](#tfn1a-ott-9-1361){ref-type="table-fn"}           28 (5.1)            12 (4.2)               
  Size of tumor (cm), n (%)                                                                              
   \<1                                                        22 (4.0)            19 (6.6)               0.072
   1 to \<2                                                   19 (3.4)            16 (5.6)               
   2 to \<3                                                   76 (13.7)           26 (9.1)               
   3 to \<4                                                   150 (27.1)          83 (29.0)              
   \>4                                                        286 (51.7)          142 (49.7)             
  Comorbidity, n (%)                                                                                     
   0                                                          272 (49.2)          207 (72.4)             \<0.0001
   1                                                          133 (24.1)          40 (14.0)              
   \>2                                                        148 (26.8)          39 (13.6)              
  Differentiation, n (%)                                                                                 
   1                                                          321 (58.0)          172 (60.1)             0.823
   2                                                          158 (28.6)          79 (27.6)              
   3                                                          74 (13.4)           35 (12.2)              
  Deep stromal invasion, n (%)                                                                           
   Yes                                                        319 (57.7)          157 (54.9)             0.439
   No                                                         234 (42.3)          129 (45.1)             
  LVSI, n (%)                                                                                            
   Yes                                                        217 (39.2)          106 (37.1)             0.539
   No                                                         336 (60.8)          180 (62.9)             
  Positive margins, n (%)                                                                                
   Yes                                                        12 (2.2)            21 (7.3)               \<0.0001
   No                                                         541 (97.8)          265 (92.7)             
  Positive nodes, n (%)                                                                                  
   Yes                                                        186 (33.6)          79 (27.6)              0.776
   No                                                         367 (66.4)          207 (72.4)             
  Positive parametrium, n (%)                                                                            
   Yes                                                        20 (3.6)            18 (6.3)               0.771
   No                                                         533 (96.4)          268 (93.7)             
  NACT, n (%)                                                                                            
   Yes                                                        78 (14.1)           89 (31.1)              \<0.0001
   No                                                         475 (85.9)          197 (68.9)             
  Adjuvant CT, n (%)                                                                                     
   Yes                                                        162 (29.3)          114 (39.9)             0.002
   No                                                         391 (70.7)          172 (60.1)             
  CCRT, n (%)                                                                                            
   Yes                                                        312 (56.4)          161 (56.3)             0.972
   No                                                         241 (43.6)          125 (43.7)             

**Note:**

Including adenocarcinoma and adenosquamous carcinoma;

including clear cell carcinoma and neuroendocrine carcinoma.

**Abbreviations:** BMI, body mass index; CCRT, concurrent chemoradiation; CT, chemotherapy; GO, gynecologic oncologist; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy.

###### 

Operative characteristics and complications

                                                      GO group (n=553)   Non-GO group (n=286)   *P*-value
  --------------------------------------------------- ------------------ ---------------------- -----------
  Para-aortic lymph node sampling/dissection, n (%)   54 (9.8)           16 (5.6)               0.038
  Surgical guidelines                                                                           
   Followed                                           466 (84.3)         213 (74.5)             0.003
   Not followed                                       50 (9.0)           41 (14.3)              
   Unknown                                            37 (6.7)           32 (11.2)              
  Operative time (min), median (range)                180 (120--300)     270 (180--600)         \<0.0001
  Estimated blood loss (mL), median (range)           350 (200--1,500)   425 (200--1,500)       \<0.0001
  Blood transfusion, n (%)                            149 (26.9)         96 (33.6)              0.046
  No of lymph nodes removed, median (range)           25 (16--33)        24 (18--33)            0.033
  Hospital stay (day), median (range)                 16 (10--21)        16 (10--21)            0.005
  Duration until PVR \<100 mL (day), median (range)   16 (12--28)        10 (7--28)             \<0.0001
  Intraoperative complications, n (%)                                                           
   Cystotomy                                          3 (0.5)            7 (2.4)                0.038
   Ureteric injury                                    8 (1.4)            7 (3.8)                0.027
   Vascular injury                                    6 (1.1)            3 (1.0)                1.000
   Bowel injury                                       3 (0.5)            1 (0.3)                1.000
  Postoperative complications, n (%)                                                            
   Cellulitis                                         13 (2.4)           2 (0.7)                0.087
   Lymphocyst infection                               22 (4.0)           4 (1.4)                0.041
   Bowel obstruction                                  12 (2.2)           4 (1.4)                0.439
   Fistula formation                                  2 (0.4)            3 (3.1)                0.002
   Deep vein thrombosis                               4 (0.7)            4 (1.4)                0.562
   Pulmonary embolism                                 1 (0.2)            1 (0.3)                1.000

**Abbreviations:** GO, gynecologic oncologist; PVR, postvoid residual urine volume.

###### 

Cox proportional hazard model of potential factors associated with recurrence-free survival in patients with cervical cancer

                                                                                                         Recurrence-free survival                                            
  ------------------------------------------------------------------------------------------------------ -------------------------- ------ --------------- ---------- ------ ---------------
  Care from a GO (yes vs no)                                                                             0.002                      0.64   (0.48, 0.84)    \<0.0001   0.57   (0.42, 0.76)
  Age                                                                                                    0.507                      1.01   (0.99, 1.02)    --         --     --
  BMI (kg/m^2^)                                                                                          0.518                      0.98   (0.93, 1.04)    --         --     --
  Tumor histology (nonsquamous vs squamous)                                                              \<0.0001                   2.44   (1.80, 3.32)    \<0.0001   1.96   (1.43, 2.70)
  Tumor stage                                                                                            \<0.0001                   1.37   (1.21, 1.55)    --         --     --
  Tumor differentiation (G1--2 vs G3)                                                                    0.050                      1.44   (1.00, 2.07)    --         --     --
  LACC (yes vs no)                                                                                       \<0.0001                   5.09   (3.56, 7.28)    0.028      0.51   (0.28, 0.93)
  Deep stromal invasion (yes vs no)                                                                      \<0.0001                   5.81   (3.87, 8.71)    --         --     --
  LVSI (yes vs no)                                                                                       \<0.0001                   2.86   (2.15, 3.80)    --         --     --
  Positive margins (yes vs no)                                                                           0.001                      4.76   (3.08, 7.36)    0.001      2.15   (1.36, 3.40)
  Positive nodes (yes vs no)                                                                             \<0.0001                   5.28   (3.94, 7.07)    \<0.0001   2.70   (1.93, 3.78)
  Positive parametrium (yes vs no)                                                                       \<0.0001                   4.84   (3.22, 7.27)    0.024      1.64   (1.07, 2.53)
  Presence of a combination of high-risk factors[a](#tfn4-ott-9-1361){ref-type="table-fn"} (yes vs no)   \<0.0001                   7.66   (5.14, 11.44)   \<0.0001   7.85   (3.98, 15.46)
  NACT (yes vs no)                                                                                       \<0.0001                   2.59   (1.94, 3.45)    --         --     --

**Note:**

High-risk factors include LACC, LVSI and greater than one-third stromal invasion.

**Abbreviations:** BMI, body mass index; GO, gynecologic oncologist; LACC, locally advanced cervical cancer; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; HR, hazard ratio; CI, confidence interval.

###### 

Cox proportional hazard model of potential factors associated with cancer-specific survival in patients with cervical cancer

                                                                                                         Cancer-specific overall survival                                             
  ------------------------------------------------------------------------------------------------------ ---------------------------------- ------- --------------- ---------- ------ ---------------
  Care from a GO (yes vs no)                                                                             0.005                              0.64    (0.47, 0.87)    0.001      0.58   (0.42, 0.81)
  Age                                                                                                    0.844                              1.00    (0.99, 1.02)    --         --     --
  BMI (kg/m^2^)                                                                                          0.947                              1.00    (0.94, 1.06)    --         --     --
  Tumor histology (NSQ vs SQ)                                                                            \<0.0001                           2.76    (1.99, 3.83)    \<0.0001   2.18   (1.55, 3.06)
  Tumor stage                                                                                            \<0.0001                           1.50    (1.30, 1.72)    --         --     --
  Tumor differentiation (G1--2 vs G3)                                                                    0.009                              1.67    (1.14, 2.46)    --         --     --
  LACC (yes vs no)                                                                                       \<0.0001                           8.20    (5.19, 12.96)   --         --     --
  Deep stromal invasion (yes vs no)                                                                      \<0.0001                           10.10   (5.84, 17.46)   --         --     --
  LVSI (yes vs no)                                                                                       \<0.0001                           3.53    (2.56, 4.87)    --         --     --
  Positive margins (yes vs no)                                                                           \<0.0001                           5.36    (3.41, 8.41)    0.001      2.32   (1.44, 3.72)
  Positive nodes (yes vs no)                                                                             \<0.0001                           6.81    (4.86, 9.54)    \<0.0001   2.85   (1.97, 4.14)
  Positive parametrium (yes vs no)                                                                       \<0.0001                           5.58    (3.64, 8.56)    0.022      1.69   (1.08, 2.66)
  Presence of a combination of high-risk factors[a](#tfn6-ott-9-1361){ref-type="table-fn"} (yes vs no)   0.001                              13.79   (7.98, 23.85)   \<0.0001   7.36   (4.10, 13.21)
  NACT (yes vs no)                                                                                       \<0.0001                           2.91    (2.13, 3.97)    --         --     --

**Note:**

High-risk factors include LACC, LVSI, and greater than one-third stromal invasion.

**Abbreviations:** BMI, body mass index; GO, gynecologic oncologist; LACC, locally advanced cervical cancer; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; NSQ, nonsquamous; SQ, squamous; HR, hazard ratio; CI, confidence interval.

###### 

Cox proportional hazard model of potential factors associated with disease-free survival and cancer-specific survival in patients with locally advanced cervical cancer

                                        Disease-free survival   Cancer-specific overall survival                                                                                                   
  ------------------------------------- ----------------------- ---------------------------------- -------------- ------- ------ -------------- ---------- ------ -------------- ---------- ------ --------------
  Care from a GO (yes vs no)            0.001                   0.59                               (0.43, 0.80)   0.001   0.59   (0.42, 0.81)   0.003      0.60   (0.44, 0.84)   0.007      0.62   (0.44, 0.88)
  Age                                   0.436                   1.01                               (0.99, 1.02)   --      --     --             0.429      1.01   (0.99, 1.03)   --         --     --
  BMI (kg/m^2^)                         0.925                   1.00                               (0.94, 1.06)   --      --     --             0.874      1.00   (0.94, 1.06)   --         --     --
  Tumor histology (NSQ vs SQ)           \<0.0001                1.92                               (1.35, 2.73)   0.007   1.65   (1.14, 2.38)   \<0.0001   2.22   (1.55, 3.18)   0.001      1.89   (1.30, 2.75)
  Tumor stage (IIA2 vs IB2)             0.700                   0.94                               (0.70, 1.27)   --      --     --             0.844      0.97   (0.70, 1.33)   --         --     --
  Tumor differentiation (G3 vs G1--2)   0.181                   1.31                               (0.88, 1.93)   --      --     --             0.049      1.50   (1.00, 2.24)   0.036      1.54   (1.03, 2.31)
  Deep stromal invasion (yes vs no)     0.005                   2.77                               (1.36, 5.65)   --      --     --             0.003      3.45   (1.52, 7.82)   --         --     --
  LVSI (yes vs no)                      0.097                   1.32                               (0.95, 1.82)   --      --     --             0.039      1.44   (1.02, 2.05)   --         --     --
  Positive margins (yes vs no)          \<0.0001                3.82                               (2.41, 6.06)   0.001   2.31   (1.42, 3.75)   \<0.0001   4.00   (2.51, 6.37)   \<0.0001   2.63   (1.62, 4.28)
  Positive nodes (yes vs no)            \<0.0001                3.34                               (2.31, 4.82)   0.000   3.13   (2.15, 4.56)   \<0.0001   3.57   (2.40, 5.32)   \<0.0001   3.21   (2.13, 4.84)
  Positive parametrium (yes vs no)      \<0.0001                2.96                               (1.94, 4.51)   0.017   1.71   (1.10, 2.65)   \<0.0001   3.14   (2.02, 4.88)   0.010      1.84   (1.16, 2.92)
  NACT (yes vs no)                      0.105                   1.29                               (0.95, 1.76)   --      --     --             0.096      1.32   (0.95, 1.83)   --         --     --

**Abbreviations:** BMI, body mass index; GO, gynecologic oncologist; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; NSQ, nonsquamous; SQ, squamous; HR, hazard ratio; CI, confidence interval.
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